12353057|t|Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist.
12353057|a|GYKI 53784 or LY303070 [(-)1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-4,5-dihydro-3-methylcarbamoyl-2,3-benzodiazepine] belongs to a new family of 2,3-benzodiazepine compounds (also called homophtalazines) selective and non-competitive antagonists at alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors. These compounds include the original GYKI-52466, its more potent derivative GYKI 53655 and the active isomer of the latter, GYKI 53784. This review summarizes current knowledge of this novel AMPA antagonist: GYKI 53784. GYKI 53784 is the most potent of the compounds in the 2,3-benzodiazepine class, blocking AMPA receptor-mediated responses. In contrast to the compounds of the quinoxalinedione family, that block AMPA as well as kainate receptors, GYKI 53784 does not block the activation of kainate receptors. Furthermore, GYKI 53784 does not act at the same receptor site as positive AMPA modulators (i.e., cyclothiazide, BDP-12, 1-BCP or aniracetam). GYKI 53784 is a powerful neuroprotective agent in both in vitro and in vivo models of AMPA receptor-mediated excitotoxicity. In contrast to NMDA receptor antagonists, whose favorable clinical actions are compromised by important side effects such as the impairment of memory functions, the selective AMPA antagonist, GYKI 53784, may be of potential clinical value, both in acute (stroke and trauma) and chronic (Alzheimer's disease, epilepsy) neurological disorders.
12353057	84	94	GYKI 53784	Chemical	MESH:C118651
12353057	96	104	LY303070	Chemical	MESH:C118651
12353057	151	161	GYKI 53784	Chemical	MESH:C118651
12353057	165	173	LY303070	Chemical	MESH:C118651
12353057	175	272	(-)1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-4,5-dihydro-3-methylcarbamoyl-2,3-benzodiazepine	Chemical	-
12353057	301	319	2,3-benzodiazepine	Chemical	-
12353057	343	358	homophtalazines	Chemical	-
12353057	514	524	GYKI-52466	Chemical	MESH:C061950
12353057	553	563	GYKI 53655	Chemical	MESH:C079692
12353057	601	611	GYKI 53784	Chemical	MESH:C118651
12353057	685	695	GYKI 53784	Chemical	MESH:C118651
12353057	697	707	GYKI 53784	Chemical	MESH:C118651
12353057	751	769	2,3-benzodiazepine	Chemical	-
12353057	856	872	quinoxalinedione	Chemical	-
12353057	927	937	GYKI 53784	Chemical	MESH:C118651
12353057	1003	1013	GYKI 53784	Chemical	MESH:C118651
12353057	1088	1101	cyclothiazide	Chemical	MESH:C004639
12353057	1103	1116	BDP-12, 1-BCP	Chemical	-
12353057	1120	1130	aniracetam	Chemical	MESH:C036466
12353057	1133	1143	GYKI 53784	Chemical	MESH:C118651
12353057	1242	1256	excitotoxicity	Disease	
12353057	1387	1417	impairment of memory functions	Disease	MESH:D008569
12353057	1450	1460	GYKI 53784	Chemical	MESH:C118651
12353057	1513	1519	stroke	Disease	MESH:D020521
12353057	1524	1530	trauma	Disease	MESH:D014947
12353057	1545	1564	Alzheimer's disease	Disease	MESH:D000544
12353057	1566	1574	epilepsy	Disease	MESH:D004827
12353057	1576	1598	neurological disorders	Disease	MESH:D009461
12353057	Negative_Correlation	MESH:C118651	MESH:D014947
12353057	Association	MESH:C118651	MESH:D000544
12353057	Association	MESH:C118651	MESH:D009461
12353057	Association	MESH:C118651	MESH:D004827
12353057	Negative_Correlation	MESH:C118651	MESH:D020521

